Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus prednisone versus placebo plus prednisone for new-onset chronic graft-versus-host disease
2016-003286-26Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Pharmacyclics. Started Mar 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2016-003286-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003286-26.